Veracyte (VCYT) has an average rating among analysts of buy, with an average price target of $18 Price: 28.75, Change: +0.24, Percent Change: +0.84 ...
Veracyte (VCYT) said in a Friday regulatory filing that Christopher Hall intends to retire as COO, effective July 1. Keith Kennedy, the company's current...
Veracyte (VCYT) said Monday a review article in Cancer Cytopathology, a journal of the American Cancer Society, describes how the technology behind...
Veracyte Inc. (VCYT) late Thursday said it plans to raise $127.9 million selling 5.5 million shares at $23.25 apiece, or 3.8% below Thursday's close....
| Address | 6000 Shoreline Court South San Francisco, California 94080 |
| Phone | +1.650.243.6300 |
| Number of Employees | 270 |
| Recent SEC Filing | 07/11/2019 4 |
| Chief Operating & Financial Officer | Keith Kennedy |
| Chief Scientific & Medical Officer | Giulia C. Kennedy |
| Chief Information Officer | Ashish Kheterpal |
| Executive Vice President & General Counsel | Julie A. Brooks |
| Price Open | $28.04 |
| Previous Close | $28.50 |
| 52 Week Range | $8.77 - 30.25 |
| Market Capitalization | $1.2 B |
| Shares Outstanding | 41.6 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 07/30/2019 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.42 |
| Beta vs. S&P 500 | N/A |
| Revenue | $92.0 M |
| Net Profit Margin | -15.51% |
| Return on Equity | -23.43% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
